AnaptysBio is a technology company.
AnaptysBio has raised $74.0M across 2 funding rounds.
AnaptysBio has raised $74.0M in total across 2 funding rounds.
AnaptysBio has raised $74.0M in total across 2 funding rounds.
AnaptysBio's investors include Frazier Healthcare Partners, Versant Ventures, Red Tree Venture Capital.
AnaptysBio is a clinical‑stage biotechnology company that discovers and develops antibody therapeutics for autoimmune and inflammatory diseases, with lead programs targeting pathogenic T cells and immune‑cell modulators and a strategy to separate its royalty assets from its biopharma operations by year‑end 2026 to sharpen strategic focus for investors.[1][5]
High‑Level Overview
AnaptysBio is focused on developing innovative immunology therapeutics — its pipeline includes rosnilimab (a pathogenic T‑cell depleter in Phase 2b for rheumatoid arthritis), ANB033 (a CD122 antagonist in early clinical testing for celiac disease) and ANB101 (a BDCA2 modulator in Phase 1a), alongside out‑licensed antibody discoveries such as dostarlimab (Jemperli) and imsidolimab that generated partnering and royalty value for the company[1][5].
The company serves patients with autoimmune and inflammatory diseases, and its work addresses unmet clinical needs by aiming to restore immune balance with targeted antibody modalities; it also serves investors through both a clinical‑stage biopharma franchise and substantial royalty assets that the company plans to separate to allow distinct investment exposures[1][5].
Origin Story
AnaptysBio was founded in 2005 and is headquartered in San Diego, California (company founding year and corporate profile reported in public company databases).[2][4]
The company grew around a proprietary antibody discovery platform (somatic hypermutation / related discovery engines) that generated multiple internally discovered antibodies and enabled out‑licensing deals (notably a PD‑1 antagonist licensed to GSK and an IL‑36R antagonist licensed to Vanda), which provided both validation and non‑dilutive funding as the pipeline advanced into clinical development[1][3].
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
AnaptysBio’s near‑term trajectory centers on clinical readouts and development decisions—updates on rosnilimab’s potential Phase 3 advancement and ANB033 expansion plans are expected in 2026, while the company’s announced intention to separate royalty assets from its biopharma operations by year‑end 2026 should materially change its capital allocation and investor profile[5][1].
If clinical data validate differentiation (deeper or more durable responses) and the corporate separation executes as planned, Anaptys could become a more focused commercial/development organization while preserving a distinct asset‑management vehicle for royalties; conversely, clinical setbacks or delays would pressure valuation given the company’s reliance on a small set of clinical programs and the timing of the corporate separation[5][1].
Overall, Anaptys sits at the intersection of antibody discovery innovation and a capital‑efficient partnering model; its influence will hinge on upcoming clinical data and the success of its strategic corporate reorganization to unlock value for different investor types[1][5].
AnaptysBio has raised $74.0M across 2 funding rounds. Most recently, it raised $40.0M Series D in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $40.0M Series D | Frazier Healthcare Partners, Versant Ventures | |
| Nov 1, 2007 | $34.0M Series B | Frazier Healthcare Partners, Red Tree Venture Capital, Versant Ventures |